Tue | Jan 26, 2021

Gov’t signs for AstraZeneca COVID-19 vaccine

Published:Saturday | November 28, 2020 | 12:07 AM
James Teague, president of AstraZeneca’s in Thailand, attends a signing ceremony at Government House in Bangkok, Thailand, on Friday, November 27.
James Teague, president of AstraZeneca’s in Thailand, attends a signing ceremony at Government House in Bangkok, Thailand, on Friday, November 27.
Thailand Prime Minister Prayuth Chan-ocha, attends a signing ceremony at Government House in Bangkok, Thailand, on Friday, November 27, 2020.
Thailand Prime Minister Prayuth Chan-ocha, attends a signing ceremony at Government House in Bangkok, Thailand, on Friday, November 27, 2020.
1
2

BANGKOK (AP):

Thailand yesterday signed a $200-million deal to procure 26 million doses of a trial coronavirus vaccine developed by pharmaceutical firm AstraZeneca, in collaboration with Oxford University. It is expected to be delivered in mid-2021.

The doses would cover 13 million people in a population of about 69 million.

Thailand’s National Vaccine Institute signed a non-refundable advance market commitment contract worth 2.38 billion baht ($79 million) with AstraZeneca, to reserve the supply of the vaccine candidate. Another 3.67 billion baht ($121 million) agreement for the purchase of the trial vaccine, known as AZD1222, was signed by the health ministry’s Disease Control Department.

“We have followed the vaccine manufacturers globally, but this group has achieved very high progress,” Thai Prime Minister Prayuth Chan-ocha said at the signing. “They are likely to be able to produce the vaccine early next year. Most importantly, we have to get ourselves ready for the domestic process, including packaging and logistics.”

Government spokesperson Anucha Burapachaisri said officials are still considering how to prioritise vaccine recipients. “Those who work closely with COVID-19 patients, for example, doctors and nurses, should be among the first people. But this needs further discussion,” he said.

Oxford and AstraZeneca reported Monday that their trial vaccine appeared to be 62% effective in people who received two doses, and 90% effective when volunteers were given a half dose followed by a full dose.

They did not mention at the time, but later acknowledged, that a manufacturing issue had resulted in “a half dose of the vaccine being administered as the first dose” to some participants, a development that led to criticism that its test results were flawed.

AstraZeneca has said it plans to conduct a new global clinical trial to make a fresh assessment of the vaccine’s efficacy.